Gemina Labs Appoints Point-of-Care Diagnostic Executive Brian Firth as Advisor

VANCOUVER, BC / ACCESSWIRE / June 8, 2022 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is pleased to announce the appointment of Brian Firth as an adviser to the Company.

Brian Firth is a proven executive from the point-of-care diagnostics sector. He spent nearly eight years at Swiss Precision Diagnostics, initially as Managing Director of Swiss Precision Diagnostics' UK subsidiary, before becoming Chief Operating Officer of the parent company, Swiss Precisions Diagnostic GmbH. Swiss Precision Diagnostics is the manufacturer of the Clearblue family of pregnancy and fertility monitoring tests. At Swiss Precision, Brian was responsible for a broad range of business processes including quality management, HR, regulatory affairs, customer service and research leadership. Swiss Precision is jointly owned by Procter & Gamble and Abbott Laboratories.

Prior to his time at Swiss Precision, Brian was a management consultant with Coopers and Lybrand working for a client roster that included Oxford Instruments, Johnson & Johnson, and Unilever. He subsequently established his own consultancy working with Inverness Medical, Agfa Healthcare, amongst others, before founding The Health Works Ltd. (a specialist operations consultancy) which was eventually sold to GE Healthcare. His career also includes time in the human wellness market, particularly human performance monitoring for applications in sports medicine and workplace diagnostics.

"I started looking at the Gemina chemistry platform in 2021," stated Brian Firth. "I believe it has the potential to take point-of-care testing by storm. It is a technology proposition that one sees perhaps once or twice in a career. I'm really pleased to be formally enrolled with the Advisory Board, and I am looking forward to helping shape the next few chapters in Gemina's development".

"Gemina is really fortunate to have engaged with Brian over the last number months, resulting in his appointment today,'" stated John Davies, Gemina's CEO. "His appointment significantly strengthens us as we move from R&D into product commercialization. We have been fortunate to attract such an exceptional cross section of deeply experienced and proficient diagnostic leaders to our Advisory Board, representing a globally significant well of expertise, so it with great humility that we welcome someone of Brian's calibre at this point in our development."

On Behalf of the Board of Directors,

John Davies
CEO

Gemina Laboratories Ltd.

About Gemina Laboratories Ltd.

Gemina Labs is a biosensor and diagnostic company with a transformative, patented, proprietary chemistry that powers next-generation testing platforms for a wide range of pathogens that affect human health and wellness. Our technology drives testing platforms that are fast, affordable and accurate, and easily self-administered. Our development pipeline includes platforms for the rapid testing of COVID-19, influenza and other viruses. Additional information on the Company can be found at www.geminalabs.com.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this Release.

Forward Looking Statements

This news release includes forward-looking information and statements, which may include, but are not limited to, information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company. Such statements include statements regarding the anticipated terms of any proposed transaction or engagement. Information and statements which are not purely historical fact are forward-looking statements. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein. Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Furthermore, the Company is presently unable to fully quantify the impact that the Covid-19 pandemic will have on its operations and recognizes that certain eventualities may affect planned or assumed performance moving forward. As such, any forward-looking information and statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward looking information and statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws.

For more information regrading the Company, please contact:
James Tansey
Telephone: 604-562-4546
Email: investor@geminalabs.com

SOURCE: Gemina Laboratories Ltd.

 


View source version on accesswire.com:
https://www.accesswire.com/704265/Gemina-Labs-Appoints-Point-of-Care-Diagnostic-Executive-Brian-Firth-as-Advisor

 

Back to news